Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hypersensitivity, Immediate: full-pipeline trial registry
A small indexed set (4 trials) with no open enrollment listed right now.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · none currently recruiting · #4,115 of 28,707 conditions by registered trial count
Hypersensitivity, Immediate: 4 US clinical trials tracked, none currently recruiting.
Hypersensitivity, Immediate is the subject of 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is David Van Sickle, running 1 of these trials.
Enrollment posture brief
Registry condition hypersensitivity-immediate
OPEN 0 | RECR 0% | LATE 1 | EARLY 1 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Hypersensitivity, Immediate has no open enrollment in this registry pull (4 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hypersensitivity, Immediate on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hypersensitivity, Immediate is recruiting below its size-band peers.
0 of 4 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
4 total, page 1 of 1
The Use of Penicillin Allergy Clinical Decision Rule to Enable Direct Oral Penicillin Challenge
Austin Health
NCT04454229
Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Regeneron Pharmaceuticals
NCT03054428
Asthma Data Innovation Demonstration Project
David Van Sickle
NCT02162576
A Study to Compare the Effects of Different Sized Particles on Cells in the Nose
University of California, Los Angeles
NCT01257191
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Hypersensitivity, Immediate records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hypersensitivity, Immediate trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hypersensitivity, Immediate page
4 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Hypersensitivity, Immediate trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- David Van Sickle sponsors the most Hypersensitivity, Immediate trials on record, review their full trial history before evaluating a specific study. See David Van Sickle's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hypersensitivity, Immediate condition card totals 4 registered trials; most-linked intervention Propeller Health intervention; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.